Michael Postow, MD

Assistant Attending Physician
Share
Share
Pictured: Michael Postow

Office Phone

646-888-4589

I am part of the Melanoma-Sarcoma Oncology Service.  I have an interest in developing clinical trials for patients with melanoma involving immunotherapeutic strategies.  My specific areas of interest include studying the immunologic effects of radiotherapy and characterizing pharmacodynamic biomarkers associated with ipilimumab outcomes.  I plan to continue bridging basic laboratory advances with novel clinical observations to improve the care of our patients.

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Michael Postow discloses the following relationships and financial interests:

  • Alma Eventos
    Provision of Services
  • Cancer Expert Now, Inc.
    Provision of Services
  • Envision Communications
    Provision of Services
  • Evicore
    Provision of Services
  • MJH Associates
    Provision of Services
  • Merck & Co Inc.
    Provision of Services
  • OncologyEducation
    Provision of Services
  • Pfizer, Inc.
    Provision of Services
  • Terranova Medica, LLC
    Provision of Services
  • UptoDate
    Intellectual Property Rights
  • Vindico Medical Education
    Provision of Services
  • high5md GmbH
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures